-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2024-519493-39-00
5
2025-12-09
High-risk Non-muscle-invasive Bladder
Cancer with Susceptible FGFR Alt
-
2024-516602-28-00
7
2025-11-21
Advanced Solid Tumors
-
2023-508612-29-00
5
2025-11-07
Advanced Melanoma
-
2024-519270-40-00
5
2025-10-30
Major Depressive Disorder
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-519883-42-00
5
2025-10-08
Non-small cell lung cancer
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-516633-12-00
5
2025-06-30
Locally advanced/ metastatic gastroesophageal junction and gastric can
-
2024-519219-32-00
5
2025-06-23
Heart Failure With Reduced Ejection Fraction
-
2023-506327-29-00
5
2025-05-14
Non-Small Cell Lung Cancer
-
2023-508322-10-00
4
2025-05-02
Cushing Syndrome
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2023-506308-24-00
10
2024-05-22
Recurrent or metastatic head and neck squamous cell carcinoma
-
2023-503317-29-00
5
2024-04-12
Metastatic renal cell carcinoma (mRCC)
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2023-507295-40-00
5
2024-02-12
Community-acquired pneumonia
-
2023-503661-28-00
5
2023-10-26
Hidradenitis Suppurativa
-
2023-504709-35-00
1
2023-08-16
Locally advanced or metastatic solid tumors
-
2023-503698-40-00
5
2023-03-23
Preeclampsia
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2023-508425-28-00
4
2022-10-24
Chronic Inflammatory Demyelinating Polyneuropathy